New Clinical Trial For AL Patients

The Amyloidosis Support Group website announces a new clinical trial for patients with primary amyloidosis (AL). This clinical trial, which is still in Phase I testing, utilizes the drug amifostine, which is a chemoprotective drug. From the clinical trial description:

Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining melphalan with a chemoprotective drug such as amifostine followed by peripheral stem cell transplantation may protect normal cells from the side effects of chemotherapy and may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

You can read about this clinical trial here.